Nucleophosmin 1 mutant regulatory axis via p14ARF and Sentrin-specific protease 3 (NPM1c/ARF/SENP3 axis)

The Nucleophosmin 1 mutant (NPM1c) regulatory axis via p14ARF and Sentrin-specific protease 3 (SENP3) is a critical pathological pathway in Acute Myeloid Leukemia (AML). In healthy cells, NPM1 resides in the nucleolus where it stabilizes the tumor suppressor p14ARF and interacts with the deSUMOylating enzyme SENP3 to maintain nucleolar homeostasis (Kuo et al., 2008). However, mutations in the NPM1 gene (NPM1c) result in the constitutive cytoplasmic localization of the protein, which sequesters p14ARF and SENP3 in the cytoplasm (Falini et al., 2005). This mislocalization leads to the proteasomal degradation of p14ARF and SENP3, effectively disabling the p53-mediated DNA damage response and disrupting ribosome biogenesis (den Besten et al., 2005). Therapeutic strategies targeting this axis primarily utilize Selective Inhibitors of Nuclear Export (SINE), such as Selinexor, to force the relocation of NPM1c back into the nucleus (Lapalombella et al., 2012). Restoring this axis is a major therapeutic goal for the approximately 30% of adult AML patients who harbor NPM1 mutations, as it reactivates essential tumor suppressive mechanisms.

Other names

NPM1c-ARF-SENP3 pathwayNPM1 mutant-p14ARF-SENP3 signaling axisNPM1c-mediated ARF degradation pathway

Inhibition of XPO1-mediated nuclear export to restore nuclear localization of NPM1c and stabilize p14ARF and SENP3, thereby reactivating p53-mediated apoptosis.